- Home
- ANAB vs PPTA Comparison
ANAB vs PPTA Comparison
Compare ANAB & PPTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- PPTA
- Stock Information
- Founded
- ANAB 2005
- PPTA 2011
- Country
- ANAB United States
- PPTA United States
- Employees
- ANAB N/A
- PPTA N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- PPTA Precious Metals
- Sector
- ANAB Health Care
- PPTA Basic Materials
- Exchange
- ANAB Nasdaq
- PPTA Nasdaq
- Market Cap
- ANAB 600.4M
- PPTA 573.6M
- IPO Year
- ANAB 2017
- PPTA N/A
- Fundamental
- Price
- ANAB $22.27
- PPTA $9.88
- Analyst Decision
- ANAB Buy
- PPTA Strong Buy
- Analyst Count
- ANAB 11
- PPTA 2
- Target Price
- ANAB $54.64
- PPTA $18.50
- AVG Volume (30 Days)
- ANAB 623.5K
- PPTA 454.1K
- Earning Date
- ANAB 11-05-2024
- PPTA 11-13-2024
- Dividend Yield
- ANAB N/A
- PPTA N/A
- EPS Growth
- ANAB N/A
- PPTA N/A
- EPS
- ANAB N/A
- PPTA N/A
- Revenue
- ANAB $57,172,000.00
- PPTA N/A
- Revenue This Year
- ANAB $207.49
- PPTA N/A
- Revenue Next Year
- ANAB N/A
- PPTA N/A
- P/E Ratio
- ANAB N/A
- PPTA N/A
- Revenue Growth
- ANAB 282.17
- PPTA N/A
- 52 Week Low
- ANAB $13.36
- PPTA $2.69
- 52 Week High
- ANAB $41.31
- PPTA $10.75
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- PPTA 52.34
- Support Level
- ANAB $18.03
- PPTA $9.46
- Resistance Level
- ANAB $22.94
- PPTA $9.92
- Average True Range (ATR)
- ANAB 1.37
- PPTA 0.69
- MACD
- ANAB 0.45
- PPTA 0.00
- Stochastic Oscillator
- ANAB 86.18
- PPTA 59.53
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About PPTA Perpetua Resources Corp.
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.